What has happened to gene therapy?

Area of Science:

• * Molecular Biology and Genetics
• * Medical Genetics and Genomics
• * Biotechnology and Therapeutic Development

Background:

• * Gene therapy has demonstrated feasibility in correcting genetic defects in monogenic disorders.
• * Conditions like severe combined immune deficiency (SCID) and cystic fibrosis have shown potential for gene therapy interventions.
• * Significant obstacles and ethical considerations remain in the clinical application of gene therapy.

Purpose of the Study:

• * To evaluate the current state and future potential of gene therapy for genetic disorders.
• * To identify key challenges and ethical issues hindering gene therapy implementation.
• * To explore the prospective applications of gene therapy in a wider range of diseases.

Main Methods:

• * Review of existing clinical trial data on gene therapy efficacy.
• * Analysis of technical challenges in gene delivery and targeting.
• * Examination of ethical frameworks and regulatory considerations for gene therapy.

Main Results:

• * Feasibility of gene correction demonstrated in monogenic disorders.
• * Obstacles and ethical concerns identified as key barriers to widespread adoption.
• * Potential for gene therapy extends beyond monogenic disorders.

Conclusions:

• * Continued research, improved delivery systems, and adherence to clinical standards are crucial.
• * Gene therapy is poised for clinical implementation in monogenic and multifactorial disorders.
• * Future applications include cancer, neurodegenerative diseases, and vascular diseases.